Piper Sandler lowered the firm’s price target on Molson Coors (TAP) to $50 from $52 and keeps a Neutral rating on the shares. The firm says it is updating its models and price targets for recently announced GLP-1 news, higher ABV headwinds, as well as tariff relief and other company specific updates. President Trump recently announced deals with Eli Lilly (LLY) and Novo Nordisk (NVO) to cut GLP-1 drug prices for Medicare and Medicaid beneficiaries in 2026 and offer the treatments directly to consumers at a discount on TrumpRX. Faster user uptake growth in the US appears directionally clear, and Piper now estimates about 20% of the U.S. population could be users by 2028.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TAP:
- Molson Coors Announces Departure of Chief Commercial Officer
- Midday Fly By: Target reports mixed Q3, Adobe buying Semrush
- DoorDash, Baidu upgraded: Wall Street’s top analyst calls
- Wells downgrades Molson Coors with better growth at AB InBev
- Molson Coors downgraded to Equal Weight from Overweight at Wells Fargo